Abstract: A topical composition and method are described for reducing attraction of host-seeking insects to human skin. The composition includes a magnesium-based or aluminum-based mineral salt in a cosmetically acceptable carrier and is applied to skin to alter skin emissions, including volatile organic compounds and metabolic byproducts associated with mosquito host-seeking behavior. The compositions may be formulated as sprays, balms, sticks, creams, gels, roll-ons, lotions, emulsions, or wipes. By modifying skin-associated chemical cues rather than merely masking odor with volatile fragrances, the compositions reduce insect attraction and may provide a non-toxic, long-lasting personal-care approach for decreasing mosquito bites and other insect interactions.

Abstract: Methods for prevention and reversal of inflammation.

Abstract: To provide an immune cell induced from an iPS cell provided with a phenotype advantageous for migration and infiltration into solid tumor sites, and for proliferation and survival of the immune cell in the solid tumor. The present invention provides an immune cell induced from an iPS cell, and expressing a cell surface molecule reactive to a tumor-related antigen, and interleukin 15. The invention further provides an immune cell induced from an iPS cell, and expressing a cell surface molecule reactive to a tumor-related antigen, and interleukin 12, interleukin 18, or interleukin 21.

Abstract: The present invention relates to methods for the selective expansion of ?? T-cell population(s), compositions and admixtures thereof and methods for using the same as a therapeutic. Non-engineered and engineered, enriched ?? T-cell populations of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders.

Abstract: The present disclosure includes compositions and methods of treating cancerous growth. For example, methods of the present disclosure may include administering a first nanoparticle composition to a subject having the cancerous growth, administering a second nanoparticle composition to the subject having the cancerous growth, and/or administering CAR-T cells to the subject having the cancerous growth. The first nanoparticle composition, the second nanoparticle composition, or both, may include tumor necrosis factor alpha and/or interferon gamma.

Abstract: The present invention relates to a traditional Chinese medicine composition for the treatment of chronic headaches and its preparation method. The composition consists of the following components by weight: 1200-1300 parts of Chuanxiong, 570-670 parts of Bai Shao, 450-550 parts of Ge Gen, 60-500 parts of Vinegar Yanhusuo, 330-420 parts of Honey-fried Jiangan, 320-420 parts of Vinegar Xiangfu, and 200-300 parts of Bai Zhi. The formulation of this traditional Chinese medicine composition is reasonable and simplified, avoiding the waste of medicinal materials. It demonstrates significant efficacy, showing a notable regulatory effect on headache-related indicators and can alleviate central sensitization in chronic migraine rats. Compared to Fluorgelazine and other traditional Chinese medicines for headache relief, it exhibits superior effects and advantages.

Abstract: The present invention relates to selected bacterial strains belonging to the Lactobacillus and Bifidobacterium species and their mixtures, compositions, and use in therapy, especially in the male urological field for the treatment of male fertility. More specifically, the invention relates to the use of specific bacterial strains in the curative or prophylactic treatment of benign prostatic hyperplasia and myometrial dysfunction. In addition, the present invention relates to selected bacterial strains, belonging to the species Lactobacillus and Bifidobacterium, and mixtures and compositions thereof, for use in a method of treatment, preferably a preventive or curative method of treatment, of male urinary diseases, preferably of benign prostatic hyperplasia (BPH).

Abstract: Provided are compositions methods of preventing, delaying or ameliorating atopic dermatitis in a breastfed infant having an increased risk of developing an atopic disease, the method comprising administering a composition comprising administering a Bifidobacterium to the breastfed infant.

Abstract: The present invention provides a combination of a vitamin mixture and a synbiotic for use in enhancing bone growth and/or bone strength, for example in a child who has suffered from and/or is suffering from stunted growth and/or faltering growth.

Abstract: An extended release formulation is provided for use in a method for the treatment of Central Precocious Puberty (CPP) in pediatric patients 2 years of age or older. The extended release formulation comprises leuprolide or a pharmaceutically acceptable salt thereof, a biodegradable polymer, and a biocompatible organic solvent. The biodegradable polymer is comprised of poly(lactide-co-glycolide) (PLG) copolymer segments, poly(lactic acid-co-glycolic acid) (PLGA) copolymer segments, poly(lactide) (PL) polymer segments, poly(lactic acid) (PLA) polymer segments, or a combination thereof. The extended release formulation is administered as a subcutaneous injection of a flowable composition that forms a solid in situ depot. The extended release formulation releases leuprolide for a period of about 6 months for the effective treatment of CPP within a pediatric patient.

Abstract: Compositions are provided for formulations of ?-defensin and/or a ?-defensin analog that are highly suitable for parenteral administration. Such formulations provide the ?-defensin and/or a ?-defensin analog in a slightly acidic buffer that includes propylene glycol. Surprisingly, Inventors have found that such formulation increase bioavailability of a ?-defensin and/or a ?-defensin analog so provided by at least a factor of 10 relative to conventional isotonic saline solutions, and that such formulations dramatically improved bioavailability in human subjects relative to animal models. Inventors have also found that such formulations advantageously exhibit low viscosity at high peptide concentrations, reducing injection volume permitting sterilization by simple filtration.

Abstract: The present invention relates to formulations of amylin analogues, and their use, for example, in the treatment of obesity and metabolic disorders such as diabetes. In particular, the present invention relates to stable aqueous liquid formulations of amylin analogues.

Abstract: Provided is a tyrosinase-based transdermal delivery system for treating vitiligo, having a core-shell structure, a core being tyrosinase, and a shell being a polymer shell. Double bonds are introduced into tyrosinase, and the surface of protein is coated with a polymer protection layer through in-situ polymerization to protect the activity of the tyrosinase, and promote the transdermal delivery of the tyrosinase. Tyrosinase nanogel can be controlled to be delivered to melanocytes deep in skin and hair follicles in a targeted manner by regulating and controlling polymerization conditions of the polymer shell to promote in-situ synthesis of melanin. The system can also load active small molecules with an anti-inflammatory function at a center of the tyrosinase, and the small molecules are released after being delivered to an inflammatory area of vitiligo in a targeted manner along with the tyrosinase nanogel, thereby relieving inflammation, and protecting the melanocytes from being damaged.

Abstract: The subject invention pertains to novel phase-separating peptide-based nucleic acid formulations and methods thereof that generate robust nucleic acid transfection in both in vitro and in vivo systems and exhibit the uprising potential for delivering nucleic acid therapeutics for the treatment of cancer and infectious diseases.

Abstract: Provided are novel linker compounds and ligand-drug conjugates, and more specifically to linker compounds comprising a short polypeptide and use thereof in preparation of ligand-drug conjugates, ligand-drug conjugates comprising the linker, and preparation and use thereof. The novel linker compounds improve the coupling efficiency of the ligand-drug conjugates as well as the homogeneity and overall stability of the conjugates, further improving the efficacy and safety of the ligand-drug conjugates.

Abstract: Disclosed is a peptide delivery system for delivering a peptide payload to a target cell or target locus and methods of delivering a peptide payload to a target locus. The peptide delivery system may include a cell, extracellular vesicle, or lipid-containing particle into which an exogenous polypeptide has been anchored, the exogenous polypeptide having a first and a second transmembrane domain connected by a loop region, which loop region comprises a first cleavage site, a peptide payload, and a second cleavage site and optionally, a targeting moiety for targeting the peptide delivery system to a target cell or target locus.

Abstract: A natural water soluble protocatechuic acid and L-theanine cocrystal composition is described. The cocrystal composition may be created by a method including solvent-assisted mechanical grinding. The natural water soluble cocrystal composition is suitable for sublingual administration, preferably to humans.

Abstract: A use of ingenol mebutate (IM) or a composition including the same in the preparation of pharmaceutical agents for tumor treatment pertain to the field of biomedicine. IM can inhibit the formation of vasculogenic mimicry (VM) following treatment with anti-angiogenic medicament. When used in combination with anti-angiogenic drugs (AADs) such as nimotuzumab (NTZ), IM inhibits the development of drug resistance to AADs, further reducing the recurrence and metastasis of nasopharyngeal carcinoma (NPC). Thereby, it enhances the survival rate and improves the prognosis of NPC patients. The disclosure has significant clinical implications and strong potential for industrial application and commercialization.

Abstract: The present application, in certain aspects, pertains to methods and compositions for the treatment of a hormone-dependent cancer (such as an endometrial cancer (e.g., endometrioid endometrial cancer) or hormone-receptor positive breast cancer), using a composition comprising nanoparticles comprising sirolimus and an albumin in combination with an estrogen suppressor (such as letrozole or fulvestrant).

Abstract: Compounds according to general formula (I) act as inhibitors of NaV1.8 and can be used in the treatment of pain.